The FDA gave the go-ahead to Orca Bio’s T cell therapy that would reduce transplant-related complications for blood cancer patients.
The FDA gave the go-ahead to Orca Bio’s T cell therapy that would reduce transplant-related complications for blood cancer patients.
The therapy will be branded …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood…
Orca Bio has jumped into the commercial market with an FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for…
Regulatory T cell-based immunotherapy approved for use in matched-donor HSCTs
Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in…
The FDA has approved an allogeneic regulatory T cell immunotherapy for use in matched-donor hematopoietic stem cell…
The U.S. Food and Drug Administration announced the approval of the first hematopoietic stem cell transplant therapy to treat…
